Antibodies that bind LGR4, their use in inhibiting neoplastic cells and in treating tumors
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Apr 25, 2017
Issued Date -
N/A
app pub date -
Jun 17, 2015
filing date -
Jun 23, 2014
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Disclosed herein are anti-LGR4 antibodies for the treatment of cancer. Antibodies disclosed herein may bind LGR4 without disrupting LGR4-RSPO1 binding or signaling, and may disrupt LGR4 signaling through Wnt that is independent of RSPO1. Also disclosed are heavy and light chain polypeptide sequences for antibodies that bind LGR4, for example without disrupting LGR4-RSPO binding or signaling.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully